Results 171 to 180 of about 4,355,944 (375)

The H3K27M mutation alters stem cell growth, epigenetic regulation, and differentiation potential [PDF]

, 2022
Najla Kfoury, Ramachandran Prakasam, Santhi Pondugula, J. S. Lagas, Scot J. Matkovich, Paul Gontarz, Lihua Yang, Hiroko Yano, A. H. Kim, Joshua B. Rubin, Kristen L. Kroll   +10 more
openalex   +1 more source

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source

Mutations in TP53 , PIK3CA , PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes

, 2017
Paul A. VanderLaan, Deepa Rangachari, Susan M. Mockus, Vanessa Spotlow, Honey V. Reddi, Joan Malcolm, Mark S. Huberman, Loren Joseph, Susumu Kobayashi, Daniel B. Costa   +9 more
openalex   +2 more sources

Plasma extrachromosomal circular DNA as a biomarker in EGFR‐targeted therapy of non‐small cell lung cancer

Molecular Oncology, EarlyView.
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard, Sarmad Mehmood, Eva Boysen Fynboe Ebert, Peter Meldgaard, Anindya Dutta, Boe S. Sorensen   +5 more
wiley   +1 more source

Resolving rates of mutation in the brain using single-neuron genomics

, 2016
Gilad D. Evrony, Eunjung Lee, Peter J. Park, Christopher A. Walsh   +3 more
openalex   +1 more source

VARS2andTARS2Mutations in Patients with Mitochondrial Encephalomyopathies [PDF]

, 2014
Daria Diodato, Laura Melchionda, Tobias B. Haack, Cristina Dallabona, Enrico Baruffini, Claudia Donnini, Tiziana Granata, Francesca Ragona, Paolo Balestri, Maria Margollicci, Eleonora Lamantea, Alessia Nasca, Christopher A. Powell, Michal Minczuk, Tim M. Strom, Thomas Meitinger, Holger Prokisch, Costanza Lamperti, Massimo Zeviani, Daniele Ghezzi   +19 more
openalex   +1 more source

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

New England Journal of Medicine, 2017
R. Stone, S. Mandrekar, B. Sanford, K. Laumann, S. Geyer, C. Bloomfield, C. Thiede, T. Prior, K. Döhner, G. Marcucci, F. Lo‐Coco, R. Klisovic, A. Wei, J. Sierra, M. Sanz, J. Brandwein, T. D. de Witte, D. Niederwieser, F. Appelbaum, B. Medeiros, M. Tallman, J. Krauter, R. Schlenk, A. Ganser, H. Serve, G. Ehninger, S. Amadori, R. Larson, H. Döhner   +28 more
semanticscholar   +1 more source

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

Mutation and cancer: statistical study of retinoblastoma.

Proceedings of the National Academy of Sciences of the United States of America, 1971
A. Knudson
semanticscholar   +1 more source

Survivin and Aurora Kinase A control cell fate decisions during mitosis

Molecular Oncology, EarlyView.
Aurora A interacts with survivin during mitosis and regulates its centromeric role. Loss of Aurora A activity mislocalises survivin, the CPC and BubR1, leading to disruption of the spindle checkpoint and triggering premature mitotic exit, which we refer to as ‘mitotic slippage’.
Hana Abdelkabir, Shalitha Wickrama Arachchige, Sally P. Wheatley   +2 more
wiley   +1 more source